Rosuvastatin Effect on Atherosclerotic Plaque Metabolism
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Atherosclerotic plaque uptake of 18F-sodium fluoride (NaF) in positron emission tomography
with computed tomography (PET-CT) was recently shown to correlate with clinical instability
in patients with CV disease. We hypothesize that rosuvastatin reduces 18F-NaF plaque uptake.
Our group will scan coronary, aortic and carotid arteries of high-risk CV subjects with 18F-
NaF-PET-CT. Individuals with 18F-NaF-positive plaques will be treated with rosuvastatin for
six months, followed by 18F-NaF-PET-CT re-evaluation.